Method of preventing or treating side effect of tumor therapy

Abstract

The present application relates to use of a nitric oxide releasing agent in the preparation of a medicament for preventing or treating diseases or disorders associated with administration of a VEGFR inhibitor and/or VEGF inhibitor. The present application further provides a method for preventing or treating diseases or disorders associated with administration of a VEGFR inhibitor and/or VEGF inhibitor in a subject. The mothed comprise administering, to a subject in need, a prophylactically or therapeutically effective amount of the nitric oxide releasing agent.

1 - 74 . (canceled) 
     
     
         75 . A method for treating hand-foot syndrome in a subject who is a cancer patient and receives administration of regorafenib, sorafenib, sunitinib, or lenvatinib, comprising administering to the subject topically an ointment, lotion or cream comprising about 0.1% (w/w) to about 1% (w/w) of nitroglycerin. 
     
     
         76 . The method of  claim 75 , wherein the concentration of nitroglycerin in the ointment, lotion or cream is 0.1% (w/w). 
     
     
         77 . The method of  claim 75 , wherein the concentration of nitroglycerin in the ointment, lotion or cream is 0.2% (w/w). 
     
     
         78 . The method of  claim 75 , wherein the concentration of nitroglycerin in the ointment, lotion or cream is 0.5% (w/w). 
     
     
         79 . The method of  claim 75 , wherein the method comprises administering to the subject topically an ointment, wherein the concentration of nitroglycerin in the ointment is 0.1% (w/w). 
     
     
         80 . The method of  claim 75 , wherein the method comprises administering to the subject topically an ointment, wherein the concentration of nitroglycerin in the ointment is 0.2% (w/w). 
     
     
         81 . The method of  claim 75 , wherein the method comprises administering to the subject topically an ointment, wherein the concentration of nitroglycerin in the ointment is 0.5% (w/w). 
     
     
         82 . The method of  claim 75 , wherein the subject receives administration of regorafenib, sorafenib, sunitinib or lenvatinib, in combination with an additional anti-tumor therapy. 
     
     
         83 . The method of  claim 82 , wherein the additional anti-tumor therapy comprises an immunotherapy agent. 
     
     
         84 . The method of  claim 83 , wherein the immunotherapy agent comprises an immune checkpoint inhibitor. 
     
     
         85 . The method of  claim 84 , wherein the immunotherapy agent comprises a PD-1 or PD-L1 inhibitor. 
     
     
         86 . The method of  claim 85 , wherein the PD-1 or PD-L1 inhibitor is Nivolumab. 
     
     
         87 . The method of  claim 85 , wherein the PD-1 or PD-L1 inhibitor is Pembrolizumab. 
     
     
         88 . The method of  claim 85 , wherein the PD-1 or PD-L1 inhibitor is Pidilizumab. 
     
     
         89 . The method of  claim 85 , wherein the immunotherapy agent comprises a CTLA4 inhibitor. 
     
     
         90 . The method of  claim 82 , wherein the additional anti-tumor therapy comprises a cytotoxic anticancer agent. 
     
     
         91 . The method of  claim 90 , wherein the cytotoxic anticancer agent is an alkylating agent or antimetabolite. 
     
     
         92 . The method of  claim 90 , wherein the chemotherapeutic agent is cisplatin, paclitaxel, carboplatin, capecitabine, fluorouracil, oxaliplatin, or carboplatin. 
     
     
         93 . The method of  claim 75 , wherein the subject receives administration of any combination of regorafenib, sorafenib, sunitinib, and lenvatinib. 
     
     
         94 . The method of  claim 82 , wherein the subject receives administration of any combination of regorafenib, sorafenib, sunitinib, and lenvatinib, further in combination with an additional anti-tumor therapy.